Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients. (Q54254889)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29546644%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

title

Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29546644%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

0 references

1 reference

1 reference

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29546644%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Adel Abdel-Moneim

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29546644%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Mohamed Abdel-Gabbar

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29546644%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Mohamed I Zanaty

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29546644%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Alaa Aboud

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29546644%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Mohamed Ramadan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29546644%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

15 March 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29546644%20AND%20SRC:MED&resulttype=core&format=json

Digestive Diseases and Sciences

20 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29546644%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29546644%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

1341-1347

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29546644%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29546644%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10620-018-5005-8

20 March 2020

exact match

0 references

cites work

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

1 reference

12 December 2020

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more

1 reference

12 December 2020

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

1 reference

12 December 2020

Sofosbuvir for previously untreated chronic hepatitis C infection

1 reference

12 December 2020

Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.

1 reference

12 December 2020

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

1 reference

12 December 2020

Global epidemiology and genotype distribution of the hepatitis C virus infection

1 reference

12 December 2020

In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir

1 reference

12 December 2020

Recent Advances in Antiviral Therapy for Chronic Hepatitis C

1 reference

12 December 2020

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens

1 reference

12 December 2020

Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection

1 reference

12 December 2020

Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection

1 reference

12 December 2020

Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.

1 reference

12 December 2020

EASL Recommendations on Treatment of Hepatitis C 2016

1 reference

12 December 2020

Management of direct antiviral agent failures.

1 reference

12 December 2020

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

1 reference

12 December 2020

Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis

1 reference

12 December 2020

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

1 reference

12 December 2020

Treatment of hepatitis C with new fixed dose combinations

1 reference

12 December 2020

Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C.

1 reference

12 December 2020

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).

1 reference

12 December 2020

10.1007/S10620-018-5005-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29546644%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference